International Patent: RTN4RL2-TARGETING SPECIFIC ANTIBODIES, ADC DRUG, AND USE OF RTN4RL2-TARGETING SPECIFIC ANTIBODIES AND ADC DRUG IN MALIGNANT TUMORS

GENEVA, June 19 -- ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY filed a patent application (CN2025/110375) for “RTN4RL2-TARGETING SPECIFIC ANTIBODIES, ADC DRUG, AND USE OF RTN4RL2-TARGETING SPECIFIC ANTIBODIES AND ADC DRUG IN MALIGNANT TUMORS”. With publication no. WO/2026/103213, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/28

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....